Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Similar Posts
Bitcoin ETFs will ‘mainstream’ the asset class, says WisdomTree CEO
Jonathan Steinberg, WisdomTree CEO, joins ‘Money Movers’ to discuss spot Bitcoin ETF and the sector outlook.
‘Fast Money’ traders Bonawyn Eison and Carter Worth reveal their acronyms for 2024
© 2024 CNBC LLC. All Rights Reserved. A Division of NBCUniversal Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Market Data Terms of Use and Disclaimers Data also provided by
American Century’s Rich Weiss still bearish on the market, says it’s difficult to see strong upside
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Closing Bell Rich Weiss, American Century Investments CIO, joins ‘Closing Bell’ to offer his bearish take on the market. 05:23 Wed, Jan 10 20244:54 PM EST
Drug name…or Star Wars planet?
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Prescription drugs have weird names. But so do planets in the Star Wars universe. We asked CNBC staffers whether they could tell the difference. 02:04 Fri, Apr 10 20159:30 AM EDT
Suze Call: Gail, Arkansas
Gail wants to know whether a 529 or whole life insurance policy is the best way to save money for her grandson’s college education.
Crowdsourcing your bottom line
Internet lingerie startup “Adore Me” aims to disrupt the U.S. lingerie market. One strategy their using, is to crowdsource the designs they bring to market.
